Genetically modified mouse models for pharmacogenomic research
- 1 September 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 5 (9) , 657-663
- https://doi.org/10.1038/nrg1429
Abstract
It is now evident that differences in the DNA sequence of genes involved with drug action can lead to interindividual differences in effectiveness and adverse reactions to therapeutic drugs. Pharmacogenomics raises the possibility that drug discovery and patient management could move from a 'one drug fits all' approach to one in which therapy is tailored to patients' genomes. Genetically modified mice that mimic human variation in drug response can provide one of the tools to move the field towards these goals.Keywords
This publication has 26 references indexed in Scilit:
- Pharmacogenetics goes genomicNature Reviews Genetics, 2003
- Postnatal anatomical and functional development of the heart: A species comparisonBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2003
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003
- Nephrogenic Diabetes InsipidusAnnual Review of Physiology, 2001
- A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple EffectorsPublished by Elsevier ,2000
- Pathophysiology of Gene-Targeted Mouse Models for Cystic FibrosisPhysiological Reviews, 1999
- The Vertebrate Myosin Heavy Chain: Genetics and Assembly Properties.Cell Structure and Function, 1997
- Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.American Journal of Respiratory Cell and Molecular Biology, 1995
- A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.Proceedings of the National Academy of Sciences, 1995
- Segregation analysis of human red blood cell thiopurine methyltransferase activityGenetic Epidemiology, 1995